$100,000 Drugs Get Targeted for Discounts Under Trump's Plan
- Such a move could make ‘huge difference,’ HHS secretary says
- Costly drugs from J&J, Merck, Bristol-Myers could be affected
This article is for subscribers only.
The key proposal in President Donald Trump’s plan to lower the price of some of the most expensive drugs would open up those treatments to price negotiation, Health and Human Services Secretary Alex Azar said.
Trump had once pledged, to the chagrin of many Republicans, that the federal government would be doing the negotiating, using its enormous buying power to drive down prices. But the plan his administration announced last week made no mention of that strategy. Instead, the new goal is to shift the coverage of some drugs so that insurers and pharmacy-benefit managers can negotiate better deals.